Przeciwciała monoklonalne w stwardnieniu rozsianym Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2012
Słowa kluczowe:
stwardnienie rozsiane, przeciwciała monoklonalne, natalizumab, rytuksymab, daklizumab, alemtuzumab, okrelizumab, ofatumumab
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule przedstawiono przegląd problematyki związanej z leczeniem stwardnienia rozsianego przeciwciałami monoklonalnymi. Omówiono zasadnicze badania kliniczne z zastosowaniem przeciwciał monoklonalnych w stwardnieniu rozsianym. Zwrócono szczególną uwagę na skuteczność i bezpieczeństwo terapii.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Gensicke H., Leppert D., Yaldizli O. et al.: Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs 2012; 26: 11-37.
2. Fontoura P.: Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. MAbs. 2010 Nov-Dec; 2(6): 670-81.
3. Polman C.H., O’Connor P.W., Havrdova E. et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006; 354(9): 899-910.
4. Tavazzi E., Ferrante P., Khalili K.: Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin. Microbiol. Infect. 2011 Dec; 17(12): 1776-80.
5. Coles A.J., Fox E., Vladic A. et al.: Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011; 10(4): 338-48.
6. CAMMS223 Trial Investigators; Coles A.J., Compston D.A., Selmaj K. et al.: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008; 359: 1786-801.
7. Barun B., Bar-Or A.: Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 2012 Jan; 142(1): 31-7.
8. Naismith R.T., Piccio L., Lyons J.A. et al.: Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010 Jun 8; 74(23): 1860-7.
9. Hawker K., O’Connor P., Freedman M.S. et al.: Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009 Oct; 66(4): 460-71.
10. Cross A.H., Klein R.S., Piccio L.: Rituximab combination therapy in relapsing multiple sclerosis. Ther. Adv. Neurol. Disord. 2012 Nov; 5(6): 311-9.
11. Kappos L., Calabresi P.A., O’Connor P. et al.: Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomized, placebo-controlled, multiplecentre trial. Lancet 2011; 387: 1779-87.
12. Castillo J., Milani C., Mendez-Allwood D.: Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin. Investig. Drugs 2009 Apr; 18(4): 491-500.
13. Rose J.W., Burns J.B., Bjorklund J. et al.: Daclizumab phase II trial in relapsing and remitting multiple sclerosis. Neurology 2007; 69: 785-9.
14. Wynn D., Kaufman M., Montalban X. et al.: Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo- controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr; 9(4): 381-90.
15. Fernandez O., Alvarez-Cermeno J.C., Arroyo-Gonzalez R.; Post-ECTRIMS group: Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Rev. Neurol. 2012 Jun 16; 54(12): 734-49.
2. Fontoura P.: Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. MAbs. 2010 Nov-Dec; 2(6): 670-81.
3. Polman C.H., O’Connor P.W., Havrdova E. et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006; 354(9): 899-910.
4. Tavazzi E., Ferrante P., Khalili K.: Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin. Microbiol. Infect. 2011 Dec; 17(12): 1776-80.
5. Coles A.J., Fox E., Vladic A. et al.: Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011; 10(4): 338-48.
6. CAMMS223 Trial Investigators; Coles A.J., Compston D.A., Selmaj K. et al.: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008; 359: 1786-801.
7. Barun B., Bar-Or A.: Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 2012 Jan; 142(1): 31-7.
8. Naismith R.T., Piccio L., Lyons J.A. et al.: Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010 Jun 8; 74(23): 1860-7.
9. Hawker K., O’Connor P., Freedman M.S. et al.: Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009 Oct; 66(4): 460-71.
10. Cross A.H., Klein R.S., Piccio L.: Rituximab combination therapy in relapsing multiple sclerosis. Ther. Adv. Neurol. Disord. 2012 Nov; 5(6): 311-9.
11. Kappos L., Calabresi P.A., O’Connor P. et al.: Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomized, placebo-controlled, multiplecentre trial. Lancet 2011; 387: 1779-87.
12. Castillo J., Milani C., Mendez-Allwood D.: Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin. Investig. Drugs 2009 Apr; 18(4): 491-500.
13. Rose J.W., Burns J.B., Bjorklund J. et al.: Daclizumab phase II trial in relapsing and remitting multiple sclerosis. Neurology 2007; 69: 785-9.
14. Wynn D., Kaufman M., Montalban X. et al.: Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo- controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr; 9(4): 381-90.
15. Fernandez O., Alvarez-Cermeno J.C., Arroyo-Gonzalez R.; Post-ECTRIMS group: Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Rev. Neurol. 2012 Jun 16; 54(12): 734-49.